Physician profile
Mark Stephen Phillips
NPI 1336633106
$1,205.10
in general payments reported to CMS, 2019-2025
12 companies · $1,205 in 2025
The $1,205 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,205.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $423.33 | 2025 | |
| Pfizer INC. | $234.93 | 2025 | |
| Collegium Pharmaceutical, INC. | $182.13 | 2025 | Belbuca |
| Novo Nordisk INC | $137.61 | 2025 | Wegovy, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $66.97 | 2025 | Trintellix |
| Astellas Pharma US INC | $42.85 | 2025 | Veozah |
| Lilly USA, LLC | $31.44 | 2025 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $21.79 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $17.66 | 2025 | Breztri |
| Edwards Lifesciences Corporation | $16.28 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Viatris Specialty LLC | $15.21 | 2025 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.90 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.